4.6 Article

Sustained release system of paclitaxel based on composite nanofibers for inhibiting renal clear cell carcinoma

Journal

JOURNAL OF MATERIALS SCIENCE
Volume 57, Issue 45, Pages 21192-21205

Publisher

SPRINGER
DOI: 10.1007/s10853-022-07907-0

Keywords

-

Funding

  1. National Natural Science Foundation of China [81974392, 82103359]
  2. Key Laboratory of Guangdong Higher Education Institutes [2021KSYS009]
  3. Guangzhou Key Laboratory of Biological Targeting Diagnosis and Therapy [202201020379]
  4. Guangzhou Core Medical Disciplines Project (2021-2023)
  5. Guangzhou Municipal Health Commission [2019TS38]
  6. Guangzhou Key Laboratory Fund [201905010004]
  7. Training Program for Academic Backbone of High Level Universities of Guangzhou Medical University [2017210]
  8. Key Clinical Specialty Project of Guangzhou Medical University (2020)
  9. Guangzhou Municipal Science and Technology Project [202102020531]

Ask authors/readers for more resources

This study developed a nanofiber system as a drug delivery system for anticancer drugs to inhibit the recurrence and metastasis of renal cell carcinoma. The nanofiber system used two types of diameters and biomaterials as drug carriers, achieving short-term and long-term release of paclitaxel to inhibit renal cancer. The results showed that the system had a lasting inhibitory effect on renal clear cell carcinoma cells.
The recurrence and metastasis of renal cell carcinoma are severe challenges in clinical treatment. At present, it is urgent to find a strategy to solve this problem and improve the therapeutic effect. In this study, we designed a programmed release system of anticancer drugs by preparing a nanofiber system with two kinds of diameters and biomaterials (polylactic acid-glycolic acid (PLGA) and silk protein) as drug carriers (paclitaxel), which inspired the occurrence and pathological microenvironment of renal cell carcinoma. The controlled degradation of PLGA nanofibers as a drug carrier achieved the short-term release of paclitaxel, which could rapidly inhibit the spread and metastasis of renal cancer, while the silk protein nanofibers as a drug carrier with slow degradation could provide the long time and continuous release of paclitaxel to prevent the proliferation of renal cancer cells and inhibit recurrence. The synergistic effect of the sustained release system of paclitaxel successfully achieved inhibition of the recurrence and metastasis of renal cell carcinoma and improve the therapeutic effect of renal cell carcinoma. The paclitaxel release profile showed that the PLGA nanofiber drug system provided controlled release of paclitaxel in the first 14 days, while the silk protein nanofiber system provided a relatively stable and long-duration release of paclitaxel (1 month). In vitro experiments showed that the sustained release system of paclitaxel had a lasting inhibitory effect on the proliferation of renal clear cell carcinoma cells. These results indicated that the sustained release system of paclitaxel could be used as a promising drug delivery system with highly efficient implementations to reduce the frequency of systemic administration and inhibit tumor growth and recurrence, which could provide a new strategy for the clinical applications in renal cell carcinoma microenvironment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available